Deutsche Bank has revised its recommendations and target prices for several European pharmaceutical companies ahead of the second-quarter earnings season, maintaining a cautious stance towards the sector. This is reported by Investing.com.
The bank remains skeptical about the sector's prospects following a brief rally at the end of the first quarter. It assesses that political risks from the United States, particularly those related to tariffs, continue to weigh on the outlook.
Roche has been downgraded to "sell" from "hold," with its target price reduced from 250 to 235 Swiss francs.
Zealand Pharma's target price has been lowered from 485 to 400 Danish kroner. Meanwhile, Argenx has been upgraded to "buy" from "hold," with its target price raised from 525 to 550 euros. Sandoz retains a "buy" recommendation, with its target price increased from 42 to 48 Swiss francs.
Swedish Orphan Biovitrum (Sobi) has been upgraded to "hold" from "sell," while CureVac maintains its "buy" recommendation, with its target price raised from $3.50 to $5.46.
